NasdaqGS - Nasdaq Real Time Price USD

Illumina, Inc. (ILMN)

122.28 +1.23 (+1.02%)
At close: April 26 at 4:00 PM EDT
125.40 +3.12 (+2.55%)
After hours: April 26 at 7:35 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
4,504,000.00
4,504,000.00
4,584,000.00
4,526,000.00
3,239,000.00
Cost of Revenue
1,760,000.00
1,760,000.00
1,612,000.00
1,372,000.00
1,036,000.00
Gross Profit
2,744,000.00
2,744,000.00
2,972,000.00
3,154,000.00
2,203,000.00
Operating Expense
2,966,000.00
2,966,000.00
2,618,000.00
3,277,000.00
1,623,000.00
Operating Income
-222,000.00
-222,000.00
354,000.00
-123,000.00
580,000.00
Net Non Operating Interest Income Expense
-19,000.00
-19,000.00
-15,000.00
-61,000.00
-8,000.00
Other Income Expense
-876,000.00
-876,000.00
-4,675,000.00
1,068,000.00
284,000.00
Pretax Income
-1,117,000.00
-1,117,000.00
-4,336,000.00
884,000.00
856,000.00
Tax Provision
44,000.00
44,000.00
68,000.00
122,000.00
200,000.00
Net Income Common Stockholders
-1,161,000.00
-1,161,000.00
-4,404,000.00
762,000.00
656,000.00
Diluted NI Available to Com Stockholders
-1,161,000.00
-1,161,000.00
-4,404,000.00
762,000.00
656,000.00
Basic EPS
-7.10
-7.34
-28.00
5.07
4.48
Diluted EPS
-7.10
-7.34
-28.00
5.04
4.45
Basic Average Shares
157,750.00
158,000.00
157,000.00
150,000.00
147,000.00
Diluted Average Shares
157,750.00
158,000.00
157,000.00
151,000.00
148,000.00
Total Operating Income as Reported
-1,069,000.00
-1,069,000.00
-4,179,000.00
-123,000.00
580,000.00
Total Expenses
4,726,000.00
4,726,000.00
4,230,000.00
4,649,000.00
2,659,000.00
Net Income from Continuing & Discontinued Operation
-1,161,000.00
-1,161,000.00
-4,404,000.00
762,000.00
656,000.00
Normalized Income
-468,170.00
-468,170.00
-721,020.00
-150,858.00
656,000.00
Interest Income
58,000.00
58,000.00
11,000.00
--
41,000.00
Interest Expense
77,000.00
77,000.00
26,000.00
61,000.00
49,000.00
Net Interest Income
-19,000.00
-19,000.00
-15,000.00
-61,000.00
-8,000.00
EBIT
-1,040,000.00
-1,040,000.00
-4,310,000.00
945,000.00
905,000.00
EBITDA
-608,000.00
-608,000.00
-3,916,000.00
1,196,000.00
1,092,000.00
Reconciled Cost of Revenue
1,760,000.00
1,760,000.00
1,612,000.00
1,372,000.00
1,036,000.00
Reconciled Depreciation
432,000.00
432,000.00
394,000.00
251,000.00
187,000.00
Net Income from Continuing Operation Net Minority Interest
-1,161,000.00
-1,161,000.00
-4,404,000.00
762,000.00
656,000.00
Total Unusual Items Excluding Goodwill
-877,000.00
-877,000.00
-4,662,000.00
1,059,000.00
--
Total Unusual Items
-877,000.00
-877,000.00
-4,662,000.00
1,059,000.00
--
Normalized EBITDA
269,000.00
269,000.00
746,000.00
137,000.00
1,092,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-184,170.00
-184,170.00
-979,020.00
146,142.00
--
12/31/2020 - 7/28/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

EXAS Exact Sciences Corporation
58.85
+0.10%
 
TMO Thermo Fisher Scientific Inc.
573.60
+0.33%
 
GH Guardant Health, Inc.
17.35
+1.11%
 
DHR Danaher Corporation
246.58
+0.32%
 
TWST Twist Bioscience Corporation
31.54
+1.48%
 
IDXX IDEXX Laboratories, Inc.
499.30
+2.06%
 
DGX Quest Diagnostics Incorporated
134.26
-0.86%
 
NTRA Natera, Inc.
91.66
+0.42%
 
LH Laboratory Corporation of America Holdings
198.40
+0.03%
 
A Agilent Technologies, Inc.
137.74
+1.00%